PMID- 36606047
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230111
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 9
DP  - 2022
TI  - Nocebo response intensity and influencing factors in the randomized clinical 
      trials of irritable bowel syndrome: A systematic review and meta-analysis.
PG  - 1018713
LID - 10.3389/fmed.2022.1018713 [doi]
LID - 1018713
AB  - OBJECTIVE: To estimate the magnitude of the nocebo response and explore its 
      influencing factors in irritable bowel syndrome (IBS). METHODS: The PubMed, 
      Embase, and Cochrane Library databases were searched up to March 2021. We 
      performed a random effects meta-analysis of the proportion of adverse events 
      (AEs) in placebo-treated patients with IBS who are involved in parallel-designed, 
      randomized, placebo-controlled trials investigating pharmacological interventions 
      and evaluated the effect of trial characteristics on the magnitude of the nocebo 
      response rate. RESULTS: A total of 6,107 studies were identified from the 
      databases. After evaluation, 53 met the eligibility criteria and were included. 
      The overall pooled nocebo response rate was 32% (95% CI: 26-38%). The most 
      commonly reported AEs were headache (9%), nasopharyngitis (7%), abdominal pain 
      (4%), and nausea (4%). The nocebo response rate was low compared with that in the 
      treatment group applying probiotics, antispasmodics, and Traditional Chinese 
      medicine, but high compared with that in antibiotic treatment group. The nocebo 
      rate in patients using diaries to record AEs was lower than the average, and was 
      higher in patients recording through checkup. DISCUSSION: Patients with IBS have 
      significant nocebo response intensity in clinical trials. Based on findings in 
      this study, we recommend the researchers pay attention to the common AEs and 
      carefully analyze the relation to the intervention.
CI  - Copyright (c) 2022 Li, Chen, He, Feng, Pei, Wang, Liu, Liu, Hou and Bai.
FAU - Li, Ruijie
AU  - Li R
AD  - Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
FAU - Chen, Fuping
AU  - Chen F
AD  - Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
FAU - He, Xuanxuan
AU  - He X
AD  - Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
FAU - Feng, Yuqing
AU  - Feng Y
AD  - Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
FAU - Pei, Qiaoqiao
AU  - Pei Q
AD  - Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
FAU - Wang, Dongke
AU  - Wang D
AD  - Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
FAU - Liu, Xinghuang
AU  - Liu X
AD  - Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
FAU - Liu, Jinsong
AU  - Liu J
AD  - Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
FAU - Hou, Xiaohua
AU  - Hou X
AD  - Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
FAU - Bai, Tao
AU  - Bai T
AD  - Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
LA  - eng
PT  - Systematic Review
DEP - 20221220
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC9807875
OTO - NOTNLM
OT  - adverse event (AE)
OT  - irritable bowel syndrome
OT  - meta-analysis
OT  - nocebo response
OT  - systematic review
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/01/07 06:00
MHDA- 2023/01/07 06:01
PMCR- 2022/12/20
CRDT- 2023/01/06 02:46
PHST- 2022/08/13 00:00 [received]
PHST- 2022/11/21 00:00 [accepted]
PHST- 2023/01/06 02:46 [entrez]
PHST- 2023/01/07 06:00 [pubmed]
PHST- 2023/01/07 06:01 [medline]
PHST- 2022/12/20 00:00 [pmc-release]
AID - 10.3389/fmed.2022.1018713 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2022 Dec 20;9:1018713. doi: 10.3389/fmed.2022.1018713. 
      eCollection 2022.